Seroprevalence of Neutralizing Antibodies Against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients Hua Zhao1, 4, 5, 6, 7, Can Xu2, 3, Xiaoli Luo2, 3, Feng Wei1, 4, 5, 6, 7, Ning Wang2, 3, Huiying Shi2, 3
, Xiubao Ren1, 4, 5, 6, 7*
1
Tianjin Medical University Cancer Institute and Hospital, China, 2Bioroc Pharmaceutical
& Biotech Company, China, 3Tianjin Genstar Vaccine Limited Liability Company, China, 4
National Clinical Research Center for Cancer, China, 5Key Laboratory of Cancer
Prevention and Therapy, China, 6Tianjin’s Clinical Research Center for Cancer, China, 7
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
l a n o si
Submitted to Journal: Frontiers in Immunology
Specialty Section: Vaccines and Molecular Therapeutics
i v o r P ISSN: 1664-3224
Article type: Original Research Article Received on: 17 Jul 2017 Accepted on: 06 Feb 2018
Provisional PDF published on: 06 Feb 2018 Frontiers website link: www.frontiersin.org Citation: Zhao H, Xu C, Luo X, Wei F, Wang N, Shi H and Ren X(2018) Seroprevalence of Neutralizing Antibodies Against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients. Front. Immunol. 9:335. doi:10.3389/fimmu.2018.00335 Copyright statement: © 2018 Zhao, Xu, Luo, Wei, Wang, Shi and Ren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
This Provisional PDF corresponds to the article as it appeared upon acceptance, after peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon.
Frontiers in Immunology | www.frontiersin.org
i v o r P
l a n o si
1
Seroprevalence
of
Neutralizing
Antibodies
Against
Human
2
Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer
3
Patients
4 5
Hua Zhao1,2,3,4,5, Can Xu6,7, Xiaoli Luo6,7, Feng Wei1,2,3,4,5, Ning Wang6,7, Huiying
6
Shi6,7 and Xiubao Ren1,2,3,4,5
7 8 9 10
1. Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
l a n o si
11
2. National Clinical Research Center for Cancer, Tianjin, China
12
3. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
13
4. Tianjin’s Clinical Research Center for Cancer, Tianjin, China
14
5. Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
15
6. Bioroc Pharmaceutical & Biotech Company, Tianjin, China
16
7. Tianjin Genstar Vaccine Limited Liability Company, China
17 18 19 20
i v o r P
Address:
Tianjin Medical University Cancer Institute & Hospital
Huanhuxi Road, Hexi District, Tianjin 300060, China
21 22
Telephone: 011-86-22-23340123
23
E-mail:
Xiubao Ren:
[email protected]
24 25 26 27 1
28
Since the preclinical results about chimpanzee adenovirus serotype-68 (AdC68)
29
based vaccine showed an encouraging results, it reminded us AdC68 may be a
30
suitable cancer vaccine vector. Previous study indicated that the seroprevalence of
31
NAbs against adenovirus was different between cancer patients and healthy
32
volunteers. Knowledge regarding the prevalence rates of AdC68 NAbs for cancer
33
patients is lacking. Therefore, assessing the pre-existence of Nabs against AdC68 in
34
cancer patients could provide useful insights for developing future AdC68-based
35
cancer vaccines.Recent studies showed the chimpanzee adenovirus serotype-68
36
(AdC68) to be a promising vaccine vector candidate because it could induce
37
protective effector and memory T cell responses against malignant cells. However,
38
few studies have described the pre-existing immunity of neutralizing antibodies
39
(NAbs) against AdC68 in cancer patients.
l a n o si
40
In this study, 440 cancer patients with eightdifferent pathological types of tumors
41
and 204 healthy adult volunteers were examined enrolled for to their evaluate the
42
NAbs against AdC68 and human adenovirus serotype-5 (AdHu5). The seroprevalence
43
of NAbs against AdC68 was much lower than that against AdHu5 in cancer subjects
44
(43.64% vs. 67.05%, P
